title: An update on the role of daratumumab in the treatment of multiple myeloma.
abstract: Monoclonal antibodies (mAbs) have emerged as a promising new drug class for the treatment of multiple myeloma (MM). Daratumumab (DARA), a CD38 mAb, has demonstrated safety, tolerability and activity in a range of clinical trials, both as monotherapy and in combination strategies for MM. The favorable efficacy results in heavily pretreated patients with advanced MM have provided the rationale for the investigation of DARA in a number of ongoing and future phase II and III trials. The general tolerability of mAbs has allowed for widespread investigation and use of DARA among a variety of MM patients, however their use requires special consideration. Infusion-related reactions (IRRs), interference with blood compatibility assays and response assessments are all unique factors related to the use of DARA. This review provides an update of the results from the DARA clinical trials conducted to date, its future plans for investigation, and practical management considerations for the use of DARA in daily practice.
authors.affiliation: Moores Cancer Center, University of California, San Diego, 3855 Health Sciences Drive #0960, La Jolla, CA 92093, USA.
authors.forename: Caitlin
authors.initials: C
authors.lastname: Costello
keywords: daratumumab; monoclonal antibody; multiple myeloma